Hims & Hers rebounds with key partnerships and launches, achieving 111% YoY revenue growth. Learn more about HIMS stock here.

Hims & Hers Health shows impressive operating leverage and a scalable business model, with massive growth potential from new ...

Short interest in Hims & Hers Health Inc rose to a record high, even as shares surged following strong first-quarter results.

President Trump signed the executive order shortly before 11 a.m. after a press conference in which he and top officials ...

An ad for compounded versions of weight-loss drug semaglutide by telehealth company Hims & Hers has attracted ... Nordisk's blockbuster weight-loss drug Wegovy, which achieved sales of around ...

Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo Nordisk, after negotiating a price cut with the company, along with Novo ...